首页> 外文期刊>JCO clinical cancer informatics. >Development and Evaluation of a Real-World Outcomes-Based Tool to Support Informed Clinical Decision Making in the Palliative Treatment of Patients With Metastatic NSCLC
【24h】

Development and Evaluation of a Real-World Outcomes-Based Tool to Support Informed Clinical Decision Making in the Palliative Treatment of Patients With Metastatic NSCLC

机译:基于现实结果的工具的开发和评估,以支持转移性NSCLC患者的姑息治疗中知情的临床决策

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE To develop and evaluate a tool for patients with stage IV non-small-cell lung cancer and their thoracic oncologists (TOs) that provides insight into real-world effectiveness of systemic treatments to support informed clinical decision making in the palliative setting.METHODS A participatory design approach was used to acquire insights from patients and TOs into preferences regarding the content and design of the web-based tool. Implementation was investigated by means of an adoption and usage rate. The appreciation of the tool was evaluated through a telephone survey with patients and a questionnaire for TOs.RESULTS From clinical data of 2,989 patients with stage IV non-small-cell lung cancer diagnosed in one of the Santeon hospitals, an interface was developed to show treatments plus both real-world outcomes and clinical trial results after selecting patient characteristics (patients like me). This prototype of the tool was finalized after discussion in a focus group with four TOs and semi-structured interviews with six patients. The tool was implemented and used by TOs in three of six Santeon hospitals (50% adoption rate). The tool was used in 48 patients (29% usage rate), of which 17 participated in the telephone survey. Ten TOs responded to the questionnaire. The responses varied from positive reactions on the clear overview of treatment outcomes to statements that the tool rarely changed treatment decisions. Overall, the majority of patients and TOs scored the tool as of added value (71% and 83%, respectively).CONCLUSION Our real-world data tool in metastatic lung cancer was appreciated in clinical practice by both patients and TOs. However, the efficacy of the implementation can be improved.
机译:目的是为IV期非小细胞肺癌及其胸部肿瘤学家(TOS)开发和评估工具,该工具可洞悉系统治疗的现实世界有效性,以支持姑息治疗中的知情临床决策。参与性设计方法用于获取患者和TOS的见解,以对基于Web的工具的内容和设计偏好。通过采用和使用率调查了实施。通过与患者的电话调查和TOS的问卷进行了电话调查,对该工具的欣赏进行了评估。来自2,989例IV期非小细胞肺癌的临床数据的分析,在其中一家Santeon医院中诊断出来,开发了一个界面以显示出一种界面选择患者特征(像我这样的患者)后,治疗加上现实的结果和临床试验结果。该工具的原型在与六名患者进行了四个TOS和半结构式访谈的焦点小组中进行了讨论之后,最终确定了。 TOS在六家Santeon医院中的三家(采用率为50%)中实施并使用了该工具。该工具用于48例患者(使用率为29%),其中17例参加了电话调查。十个托斯对问卷回答。这些反应从对治疗结果的清晰概述到工具很少改变治疗决策的陈述的反应不等。总体而言,大多数患者和TOS对该工具的额外值进行了评分(分别为71%和83%)。判断我们的转移性肺癌现实世界数据工具在临床实践中都得到了临床和TOS的赞赏。但是,可以提高实施的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号